IDH2 and central nervous system cancer: To further confirm the diagnostic potential of the identified signature, we evaluated its expression in serum samples of 15 glioma patients (8 IDH-wt, 7 IDH-mut) and 15 age and gender-matched healthy subjects (Table 1).